ChatGPT and GPT-4, both developed by OpenAI, have taken the world by storm with their new approaches to large language models. Their potential applications are far-reaching, from Natural Language Processing (NLP) in biomedicine and healthcare to their more wide-reaching implications in the industry. In this overview discussion, we will provide a complete review of large language models (LLMs) and how they can be applied to medical contexts, highlighting their potential to tackle current challenges, encourage innovation, and refine outcomes.
Dr. Shubo Tian is a research scientist under the tutelage of Dr. Zhiyong Lu. He has significant experience in LLMs, and he applies them to biomedical and clinical research projects, including information retrieval, entity recognition, entity linking, and health outcome prediction. With a PhD in statistics, Dr. Shubo Tian has a broad experience in the field.
Dr. Qiao Jin is a researcher scientist in the BioNLP team headed by Dr. Zhiyong Lu at NCBI/NLM/NIH. His M.D. degree is from Tsinghua University. His research focuses on deep learning, natural language processing, and their utilization in biomedicine. He has published around 20 peer-reviewed papers in EMNLP, NAACL, and SIGIR. These include BioELMo, one of the first language models utilized in biomedicine, and PubMedQA, a popular biomedical question-answering benchmark for evaluating LLMs. Other accomplishments include winning the first BioBank Disease AI Challenge, the TREC 2020 Precision Medicine track and being awarded the Best NLP Paper Award from the International Medical Informatics Association in 2021 for his work on EBM-Net.
OpenAI is the world’s leader in discussing AI technology and sharing their advances through open sourcing. Their mission is to develop safe Artificial General Intelligence (AGI) together with the whole world. OpenAI focuses its research on Natural Language Processing (NLP), Computer Vision, and Robotics, among other topics, for applications in healthcare, education, transportation, and more. Their belief is that long-term, open-access AGI solutions should be accessible to everyone, which is why they dedicate their efforts to advancing their research as quickly and openly as possible.
